PETTERSSON, KNUT,CAMBER, OLA,SEXTON, DAN,NIXON, ANDREW E.
申请号：
MX2014001313
公开号：
MX2014001313A
申请日:
2012.08.08
申请国别(地区):
MX
年份:
2014
代理人:
摘要：
The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein - (a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17 a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18 and a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21 or 22 and/or (b) the VL domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR4 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 23 or 24 a CDR5 sequence comprising an amino acid sequence having at least 14%, 28%, 42%, 57%, 71%, 85% or 100% sequence identity to the sequence of SEQ ID NO: 25 a CDR6 sequence comprising an amino acid sequence having at least 11%, 22%, 33%, 44%, 55%, 66%, 77%, 88% or 100% sequence identity to the sequence of SEQ ID NO: 26.La presente invención se relaciona con un anticuerpo o fragmento de anticuerpo con capacidad de unión a fosforilcolina y/o un conjugado de fosforilcolina, en la que el anticuerpo o fragmento de anticuerpo comprende un dominio de cadena pesada variable (VH) y/o un dominio de cadena
